Results 111 to 120 of about 926 (182)

A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [PDF]

Cureus
Meher D, Das S, Choudhury A, Sahoo D, Sahu SK, Agarwal V, Prusty B, Ketan Das B, Chappalagavi AS, Gupta S, Sreekumar V.   +10 more
europepmc   +1 more source

Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis. [PDF]

Cureus
Kak MC.
europepmc   +1 more source

Impact of Saroglitazar on Liver Stiffness Measurements in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Compensated Cirrhosis: A Single-Arm Study. [PDF]

Cureus
Roy A, Chakraborty S, Jajodia S, Goenka U, Tewari A, Sonthalia N, Ghoshal UC, Goenka M.   +7 more
europepmc   +1 more source

Evaluation of Effectiveness and Tolerability of Saroglitazar in Metabolic Disease Patients of India: A Retrospective, Observational, Electronic Medical Record-Based Real-World Evidence Study. [PDF]

Cureus
Das S, Gupta S, Lathia T, Swain J, Mittal S, Kumar S, Dm M, Garg N, Teja R, Beatrice A, Sooragonda BG, Mohd Razi S, Jaiswal A, Jhaveri KS, Shah S, Verma G.   +15 more
europepmc   +1 more source

Therapy in diabetic dyslipidemia.

Indian J Pharmacol
Maheswari U.
europepmc   +1 more source

PPARidgm shifts in the treatment of metabolic dysfunction-associated steatotic liver disease. [PDF]

Hepatology
Abushamat L, Abushamat L, Barb D.
europepmc   +1 more source

Nuclear Receptor-Targeted Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Int J Drug Discov Pharm
Zhou Y, Liu Z, Cui D, Qi X, Zhang H.
europepmc   +1 more source

In Silico Analysis of Saroglitazar and Ferulic Acid Binding to Human Ketohexokinase: Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [PDF]

Cureus
Tiwari K, Kumar B, Tiwari A, Dhamija P, Vardhan G, Dehade A, Kumar V.   +6 more
europepmc   +1 more source

PPAR Agonists: The Next Innovation in Hepatology. [PDF]

Can Liver J
Chandok N, Yoshida EM.
europepmc   +1 more source

Primary biliary cholangitis. Treatment options in 2025. A narrative review. [PDF]

Front Immunol
Angelara M, Papachristou K, Papatheodoridi M, Nasiri-Ansari N, Karagiannakis DS, Androutsakos T.   +5 more
europepmc   +1 more source